<DOC>
	<DOC>NCT00110903</DOC>
	<brief_summary>The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.</brief_summary>
	<brief_title>Treatment for Subjects With Active Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Fulfill the 1987 American Rheumatism Association (ARA) criteria for RA Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of up to 25 mg a week is permitted Screening lab results must demonstrate: AST and ALT less than or equal to 2 times the upper limit of normal hemoglobin greater than or equal to 8.5 g/dL; Platelet count greater than or equal to 125,000/cm3; White blood cell count (WBC) greater than or equal to 3500 cells/cm3; Serum creatinine less than or equal to 2 mg/dL Before any study specific procedure is performed, the subject must provide informed consent for participation in the study Previous receipt of etanercept Receipt of antibody to (tumor necrosis factor) TNF alpha or other TNF inhibitors within 90 days of Day 1 Currently enrolled in other investigational device or drug trials, or participation in investigational trial within the past 30 days Receipt of intraarticular corticosteroids within 14 days prior to Day 1 Receipt of any diseasemodifying antirheumatic drugs (DMARDs) within 28 days of Day 1 Receipt of cyclophosphamide within 6 months of Day 1 Concomitant corticosteroids greater than 10 mg/day of prednisone (or equivalent) during 14 days prior to Day 1 Dose of nonsteroidal antiinflammatory drug (NSAID) must be stable for 14 days prior to Day 1 and must not exceed the recommended dose in the product information sheet Subject is not using adequate contraception Subject is pregnant or breastfeeding Subject has significant concurrent medical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>etanercept</keyword>
	<keyword>Immunex</keyword>
	<keyword>Amgen</keyword>
</DOC>